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Adult T cell leukaemia/lymphoma (ATL) is a highly het-
erogeneous neoplasm caused by human T cell lympho-
tropic virus type 1 (HTLV-1) infection. Shimoyama et al
first proposed a prognostic classification based on clinical
features. However subsequent studies have highlighted
even greater heterogeneity and progression from indolent
to aggressive subtypes. The molecular basis for this het-
erogeneity and progression remains unknown. Our aims
were to identify molecular markers that characterize this
heterogeneity and progression. We studied expression of
T-cell markers and clonality (Ligation Mediated PCR) on
peripheral blood mononuclear cells in samples collected
from HTLV-1 infected patients (16 asymptomatic carrier
[AC], 18 with HTLV-1-associated myelopathy [HAM], 18
with indolent ATL [five smouldering & 13 chronic] and
seven with acute ATL) attending the National Centre for
Human Retrovirology, London. 11/18 indolent ATL
required no systemic treatment and one progressed to
acute ATL. The remainder required systemic therapy and
all except one achieved complete remission with zidovu-
dine/interferon. 6/7 with acute ATL had primary refrac-
tory disease. Clonality testing showed no dominant
clones in the AC, patient with HAM and 6 of the 11
patients with indolent ATL who didn’t require systemic
therapy. We confirmed CD4+CCR4+ as the main reser-
voir of HTLV-1 infection. These CD4+CCR4+ T cells
had CD7+CD25+CD26+CD127+CCR7-immunopheno-
type in AC, HAM and indolent ATL with no dominant
clones. CD7 down-regulation within CD4+CCR4+ T cells
identified ATL patients with dominant clone(s). CD127
down-regulation within CD4+CCR4+ T cells was present in
all indolent ATL patients which required systemic therapy.
Nine patients with ATL (all acute and two indolent) had
CCR7 up-regulation of which all but two had primary
refractory disease. Longitudinal follow up in six patients
showing changing immunophenotype which correlated with
clinical features and prognosis. In conclusion CD7, CD127
and CCR7 expression within CD4+CCR4+ infected cells
further characterises the heterogeneity within ATL with
therapeutic implications.
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